As a national high-tech enterprise group, Jumpcan Pharmaceutical – located in the Taixing Economic Development Zone in Taixing city, in East China's Jiangsu province – was recently included on the list of the Top 10 Most Valuable Pharmaceutical Listed Companies in China in 2023.
Based on evaluation scores for industry, management and capital metrics, the top 100 listed pharma groups were selected as candidate companies.
Then the top 10 listed companies were selected, based on their three-year market value growth rate from 2020 to 2022.
For its part, Jumpcan Pharmaceutical has maintained an upward growth trajectory over the past few years. In 2022, its operating revenue hit 9.0 billion yuan ($1.26 billion), for a year-on-year increase of 17.9 percent.
In recent years, the company has continued to increase its research and development expenditure and what's more, it has launched an estimated 20 new Chinese and Western medicine products.
In addition, it has also worked closely with different companies to introduce innovative drugs, striving to meet the specific medication needs of patients.
Things whirl into gear at the Jumpcan production plant. [Photo/WeChat account: txfabu]